겨울 심포지움
2018겨울초록
발표자 및 발표 내용
소속 |
|
---|---|
발표구분 |
|
구두발표 | |
포스터발표 |
|
Keyword |
|
주저자
이름 |
|
---|---|
소속 |
|
국가 |
|
공동저자
공동저자 |
|
---|
접수자
이름 |
|
---|---|
소속 |
|
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease that is closely linked to obesity, insulin resistance, hyperglycaemia and hyperlipidaemia. NAFLD progression encompasses simple steatosis, Non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. The most common NAFLD study has focused on difference between healthy individual and NAFLD patient. However, metabolic difference following liver disease progression is still unclear and distinguishing NASH from simple steatosis currently requires a liver biopsy. So, we need to find disease occurrence at early stage of NAFLD and treat properly following liver histology by non-biopsy method.
We performed a lipid profiling to find metabolic difference between healthy individual (No NAFLD), simple steatosis, NASH and altered metabolites contribute to liver disease progression. This comprehensive lipid metabolic profiling performed on 350 serum samples from humans with 65 healthy individuals, 149 simple steatosis and 136 NASH patients. Serum metabolites were analyzed using ultra-performance liquid chromatography/quadrupole time-of flight mass spectrometry (UPLC/Q-TOF MS) coupled with statistical analysis. Principal Component Analysis (PCA) and Partial Least Squares for Discriminant Analysis (PLS-DA) were performed to visualize scatter score plots.
We found metabolic difference between healthy individuals (No NAFLD), simple steatosis and NASH. Specific lipid metabolites were altered depending on NAFLD progression such as Diacylglycerol (DAG), free fatty acid (FFA), lysophosphatidylcholine (LysoPC), phosphatidylinositol (PI) and triacylglycerol (TAG). This study can be a useful tool to distinguish NAFLD progression and we can suggest different approaches to diagnosis NAFLD at early stage by non-biopsy method.
게시물수정
게시물 수정을 위해 비밀번호를 입력해주세요.
댓글삭제게시물삭제
게시물 삭제를 위해 비밀번호를 입력해주세요.